SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, single arm phase I / II clinical study in mCRPC subjects who
failed to receive docetaxel chemotherapy, abitolone acetate and / or enzalutamide (including
its analogues) for the treatment of BRCA mutations in germ cells and / or somatic cells.